ERA-NET Patho Geno Mics WP 1 Status-quo of

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape WP 2 Policy maker workshop of common understanding: Survey on the national programmes 7 th April 2005, Bonn ERA-NET Patho. Geno. Mics M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics 12 24 36 48 60 WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Month 0 WP 10 DE Consortium management WP 1 DE Status-quo of partner programmes WP 2 DE Knowledge base for RTD strategies WP 3 FR Strategic and analytic activities WP 4 FR Economic exploitation and job creation WP 5 FI Support for transnational consortium building WP 6 AT Human resources development and mobility WP 7 HU Management concept and tools WP 8 SP Implementing transnational activities Contracts 1 st round Contracts 2 nd round WP 9 IL Science and society issues M. Karrasch, FZJ 13. 01. 2005 9/04 9/05 9/06 9/07 9/08 9/09

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Deliverable No. : Delivery date: Nature: Dissemination level: due Month 5 (in January 2005) Report PP Aim: M. Karrasch, FZJ 13. 01. 2005 D 1. 2 Information documents on the national programmes Basis for development of best practices in programme implementation and management

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Questionnaire: Survey on the national RTD programmes § General Programme Description: A 1: A 2: A 3: § Part A: General Programme Information History and Road Map of the Programme / Project statistics Part B: Programme management and implementation approaches B 1: Programme Initiation B 2: Application / Submission Procedure B 3: Evaluation Process B 4: Financial modalities, Legal and Contractual Framework B 5: Project management, administrative procedures and Review of programme and projects Questionnaire: Survey on the national RTD landscape § Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Part A: General Programme Description A 1: General Programme Information A 2: History and Road Map of the Programme A 3: Programme / Project statistics Part B: Programme management and implementation approaches B 1: Programme Initiation A: General Programme Description B 2: Application / Submission Procedure B 3: Evaluation Process B 4: Financial modalities, Legal and Contractual Framework B 5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape A: General Programme Description AT Preceding Programmes: no Programme Name: GEN-AU – Austrian Genome Research Programme Owner: BMBWK – Federal Ministry of Education, Science and Culture Programme Management Agency: Programme Office GEN-AU Part of the larger Programme: no Topic: genome research Objective: e. g. enhance national competitiveness, strengthen research capacities, inprove conditions for investments Start Year: 2001 End year: 2010 Further information: www. genomik. gen-au. at Total No. of funded projects: 2 No. of running projects: 2 M. Karrasch, FZJ Next update 13. 01. 2005 / redesign: in process Funding by: BMBWK 100% Total funding volume per year: 10. 0 mio € (2004) (0. 47 mio € Pathog. ) Fixed Bugdet: yes Funded by the Programme: - 2 Universities - 1 public Research Institute

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape A: General Programme Description FI Preceding Programmes: no Programme Name: MICMAN – Microbes and Man Programme Owner: Academy of Finland The Swedish Foundation for Strategic Research Programme Management Agency: National Public Health Institute Part of the larger Programme: no Topic: research on human-relevant microorganisms Objective: increase the knowledge of the interaction between host and microbe and apply this knowledge Start Year: 2003 End year: 2005 Further information: www. aka. fi/micman Total No. of funded projects: 15 No. of running projects: 15 ( 7 cons. of 2 -4 Res. groups) M. Karrasch, FZJ 13. 01. 2005 update Next / redesign: none Funding by: Research Academy 76% Private foundation 24% Total funding volume per year: 1. 8 mio € Fixed Bugdet: yes Funded by the Programme: - 7 Universities - 2 public Research Institutes - 1 Regulatory Body

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape A: General Programme Description FR Preceeding Programmes: Funding by: - - Programme Name: Programme Owner: a s at od Programme Management Agency: Part of the larger Programme Topic: Objective: Start Year: End year: Further information: N bm u ted it 8 Fixed Budget: yes/no Total No. of funded projects: List of running projects: M. Karrasch, FZJ 13. 01. 2005 Next update / redesign: Funded by the Programme: -

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape A: General Programme Description DE Preceding Programmes: no Programme Name: Competence Center Patho. Geno. Mik Programme Owner: BMBF – Federal Ministry of Education and Science Programme Management Agency: PTJ Part of the larger Programme: Geno. Mik (Genome Research in microorganisms) Topic: genome research on bacteria (Geno. Mik) Objective: use of the potential of microbial genomes for e. g. defeating human diseases Start Year: 2001 End year: 2006 Further information: www. genomik. uni-wuerzburg. de Total No. of funded projects: 47 No. of running projects: 44 M. Karrasch, FZJ 13. 01. 2005 Next update / redesign: none Funding by: BMBF (88. 9%) involved companies (11. 1%) Total funding volume per year: 3. 63 mio € (BMBF) (2003) Fixed Bugdet: yes Funded by the Programme: - 13 Universities - 2 Medical Centres - 4 public Research Institutes - 6 Companies

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape A: General Programme Description HU Preceding Programmes: Funding by: Programme Name: Programme Owner: Programme Management Agency: Part of the larger Programme: Topic: Objective: Start Year: nd year: Further information: as at od bm u ted it N Total No. of funded projects: No. of running projects: Next update / redesign: M. Karrasch, FZJ 13. 01. 2005 Total funding volume per year: Fixed Bugdet: Funded by the Programme:

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape A: General Programme Description IL Preceding Programmes: no Funding by: CSO-MOH 100% Programme Name: NA Programme Owner: CSO-MOH – The Chief Scientist Office, Ministry of Health Programme Management Agency: NA Part of the larger Programme: no Topic: Objective: Start Year: continous End year: continuos Further information: www. health. gov. il Total No. of funded projects: 14 No. of running projects: 4 M. Karrasch, FZJ 13. 01. 2005 Next update / redesign: none Total funding volume per year: 0. 16 mio € (2003) Fixed Bugdet: no Funded by the Programme: - Universities - Medical Centres - public Research Institutes

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Preceeding Programmes: A: General Programme Description LV - funct. Stability of microb. cultures -Genotoxicity by microorganisms -Mol. Studies on Borrellia burgd. Funding by: - LCS Programme Name: Molecular and epidemiological study of multiresistence and genetic variability of infections Programme Owner: Latvian Council of Science Programme Management Agency: NA Part of the larger Programme NA Topic: Objective: Start Year: 1998 End year: 2005 Further information: www. lzp. lv Total No. of funded projects: No. of running projects: 9 M. Karrasch, FZJ 13. 01. 2005 Total funding volume per year: 0, 08 mio € Fixed Budget: yes Funded by the Programme: - 100% Universities 9 Next update / redesign: 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape A: General Programme Description PT Preceeding Programmes: - Programme Name: Programme Owner: Programme Management Agency: Part of the larger Programme Topic: Objective: Start Year: End year: Further information: at od as bm u ted it Funding by: - Total funding volume per year: . . mio € N Fixed Budget: yes/no Total No. of funded projects: List of running projects: M. Karrasch, FZJ 13. 01. 2005 Next update / redesign: Funded by the Programme: -

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape A: General Programme Description SV Preceeding Programmes: - No / yes Programme Name: (10 different programmes) Programme Owner: Ministry of Higher Education, Science and Technology Programme Management Agency: programme managers in diverse institutions/Universities Part of the larger Programme: national programme for financing research programmes Topic: 1. target research programme 2. mol. Biology of microorganisms; pharmacolog. Chemistry; nutrition and ecology of gastroint. Tract; toxins and biomembranes etc. Start Year: 2001 / 2004 End year: 2006 / 2008 Funding by: - 100% MESC - 47% Min. of Agric. For. + Food - 6% Min. of Health Total funding volume per year: 0, 496 mio € 2004 (6 th them. Prior. ) Fixed Budget: no Funded by the Programme: - 11 Universities Further information: website in slovenian language - 4 Medical Centers -39 Public Res. Inst. -1 priv. res. Inst. Total No. of funded projects: 800 Next update / redesign: 2006 / 2008 List of running projects: 450 -1 company M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Preceding Programmes: Yes National R&D plan 2000 -03 Programme Name: A: General Programme Description ES 1. Strategic Action on Genomics and Proteomics Funding by: MEC 100% 2. Biotechnology Programme Owner: Ministry of Education and Science Programme Management Agency: NA Part of the larger Programme: National Plan of R&D Topic: different topics (e. g. genomics, proteomics etc. ) Objective: functional analysis of genomes of human pathogens, characterisation of novel targets, pathogenicity mechanisms, hostpathogen-interactions, development of diagnostic tools Start Year: 2004 End year: 2007 Further information: web site in national language Total No. of funded projects: 56 No. of running projects: 31 M. Karrasch, FZJ 13. 01. 2005 Next update / redesign: 2007 Total funding volume per year: 1. 42 mio € (2004) Fixed Bugdet: no Funded by the Programme: - 19 Universities - 4 Medical Centres - 10 public Research Institutes

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Next Programme update / redesign Partner Update / redesign date Austria In process Finland No re-design France Germany Programme ends 2006; no update, but new programme Hungary Israel Continous programme Latvia 2005 Portugal Slovenia Spain M. Karrasch, FZJ 13. 01. 2005 2006 2007

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape funded Institutions M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Project Analysis (projects related to Pato. Geno. Mics) Partner Total no. of projects Range of annual budgets (1000 €) Average annual project budget (1000 €) Average duration of a project (months) Austria 2 150 - 320 240 27 Finland 15 (7 consortia of 2 -4 groups) 17 - 117 63 36 47 (9 project groups of 1 -7 groups) 31 - 389 80 57 Israel 14 15 - 29 15 12 Latvia 9 2 – 10 8 96 NA / 67 – 403 6 / 135 36 / 60 12 – 165 / 6 - 130 59 / 44 36 / 36 France Germany Hungary Portugal Slovenia Spain M. Karrasch, FZJ 13. 01. 2005 56

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Part A: General Programme Description A 1: General Programme Information A 2: History and Road Map of the Programme A 3: Programme / Project statistics Part B: Programme management and implementation approaches B 1: Programme Initiation B 2: Application / Submission Procedure B 3: Evaluation Process B 4: Financial modalities, Legal and Contractual Framework B 5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Programme Design Process Partner Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia Spain M. Karrasch, FZJ 13. 01. 2005 Top-down (idea was born and implemented by the funding authority) Bottom-up (idea was born by others e. g. beneficiaries of funding)

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Scientific communities: AT, FI, IL, LV, SL, ES Ministries AT – BMBWK DE – BMBF • Scientific Advisory Board: AT, DE, LV • Research Councils: AT, LV, SL Ministries/funding authorities/Committees AT – BMBWK FI – Steering Programme Committee DE – BMBF IL – CSO-MOH LV – Program leader SL – Ministry of Science and Technology ES – MEC First idea Programme / Call Contents / text M. Karrasch, FZJ 13. 01. 2005 Boards/ institutions: influence Research councils AT, LV, SL Analysis Initiation phase: Who influences the programme design? Editing of the Call text

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Part A: General Programme Description A 1: General Programme Information A 2: History and Road Map of the Programme A 3: Programme / Project statistics Part B: Programme management and implementation approaches B 1: Programme Initiation A: General Programme Description B 2: Application / Submission Procedure B 3: Evaluation Process B 4: Financial modalities, Legal and Contractual Framework B 5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Electronical Application/Submission System Partner Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia Spain M. Karrasch, FZJ 13. 01. 2005 Electr. System used No electr. system

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Rules for Submission System obligatory optional Partner Electr. System Austria Not available Finland Paper Version Most common subm. way Paper Version Signature only Electr. System France Germany both Hungary Israel Latvia Portugal Slovenia Spain M. Karrasch, FZJ 13. 01. 2005 Not available Paper Version Electr. System

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Application Support Partner Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia Spain M. Karrasch, FZJ 13. 01. 2005 Written Manual Electronic guidance Helpdesk / contact person

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Application Process: 1 step or 2 step approach Partner Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia Spain M. Karrasch, FZJ 13. 01. 2005 1 step-approach (full proposals) 2 step-approach (draft and full proposal

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Summary: Application / Submission Procedure Approach: 1 -step full proposals: DE, IL, LV, SL, ES Rules of procedure by: - ministry: AT, DE, IL, SL, ES - Academy/Council: FI, LV Approach: 2 -step Drafts + full proposals: AT, FI Steps during Application • (draft proposal submission) • (draft proposal evaluation): AT, FI • full proposal submission • full proposal evaluation: DE, IL, LV, SL, ES Structure of draft: - Short description of the project - Organisational and scientific concept M. Karrasch, FZJ 13. 01. 2005 Elements of full proposals: - Name, coordinates, CV researcher(s) - scientific/technical description - Cost and time schedule - Management/organisation of networks - HR/ethical aspects - Relevance to programme - Relevance to industrial application Submission: -Electronically: FI, DE, IL, LV, ES -paper: AT, FI, DE, IL, LV, SL Support of applicants by: - Written manual: all except LV - Electr. Guidance: all - Helpdesk/contact person: all

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Is the call permanently open or are there cut-off dates? Partner Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia Spain M. Karrasch, FZJ 13. 01. 2005 Permanently open (no direct competition of proposals) Cut-off dates (direct competition of proposals)

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Part A: General Programme Description A 1: General Programme Information A 2: History and Road Map of the Programme A 3: Programme / Project statistics Part B: Programme management and implementation approaches B 1: Programme Initiation A: General Programme Description B 2: Application / Submission Procedure B 3: Evaluation Process B 4: Financial modalities, Legal and Contractual Framework B 5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Evaluation Process - Evaluation by: Partner Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia Spain M. Karrasch, FZJ 13. 01. 2005 Funding authority External advisory Peer review board Hearing of applicant Presentation by applicant

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Evaluation Process: Stakeholders present among the evaluators Partner Ministry Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia Spain M. Karrasch, FZJ 13. 01. 2005 Management Agency Research Council Industry Organisation Company Single Scientist Scientific Experts Socie-ties from abroad other

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Evaluator characteristics Evaluators • • • Evaluation by funding agency/authority: AT, FI, IL, LV, SL, ES Evaluation by external advisory board: AT, FI, DE, SL, ES Evaluation by peer review: AT, IL, SL From abroad: AT, FI, DE, LV, ES M. Karrasch, FZJ 13. 01. 2005 From Industry: AT, (IL), LV, ES Standing board: DE, LV, SL

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Are the Evaluators known to the Applicants? Partner yes Austria Finland After the funding decision France Germany Some are known Hungary Israel Latvia Portugal Slovenia Spain M. Karrasch, FZJ 13. 01. 2005 Known post evaluation no

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Can the final Evaluation result be overruled? Partner yes Austria final decision is subject to the ministry Finland final ranking by the programme Steering committee France Germany Evaluation may be overruled by the project management agency and the ministry Hungary Israel Latvia Written complaint to Latvian Council of Science Portugal Slovenia Spain M. Karrasch, FZJ 13. 01. 2005 Final decision by the funding bodies no

0 M. Karrasch, FZJ 13. 01. 2005 Evaluation criteria 3 expertise, mobility 5 Transfer of 9 Training aspects 10 Societal value of proposal 20 Scientific quality 13 programme 15 Relevance to the infrastructure 7 Relevance to industrial Relevance to written proposal 5 standard of management 7 Project/resource applicant / team 13 potential of 2 Multidisciplinaritiy 25 of applicant / team 15 scientific record potential, novelty, Innovative Internationality competitiveness 5 International Gender issues 5 Ethical issues score ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Analysis: Evaluation Criteria 21 19 14 10 7 4

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Analysis: most important Evaluation Criteria M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Analysis: most important evaluation criteria Ranking Evaluation criteria Score points 1 Innovative potential, novelty, originality 21 2 Scientific quality of proposal 19 3 Relevance to industrial application and commercialisation 15 4 Relevance to the programme 14 5 potential of applicant / team 13 5 scientific record of applicant / team 13 M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Is it possible to change the rules of the application/evaluation procedure? possible impossible Partner Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia M. Karrasch, FZJ 13. 01. 2005 Spain Change of application/ evaluation procedure

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape How long does it take from publication of a call till start of a project? 14 Time from funding notification of funding authority/agency till project start 12 10 8 Time from full proposal evaluation till funding notification of funding authority/agency 6 Time from full proposal submission till full proposal evaluation months 4 Time from draft proposal evaluation till full proposal submission 2 Time from draft proposal submission till draft proposal evaluation Partner M. Karrasch, FZJ 13. 01. 2005 n Sp ai a en i Sl ov en i a a vi La t ra el an y Is Sl ov G er m an d Fi nl Au st ria 0 Time from call publication to draft (full) proposal submission

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape project statistics: Average success rate of applications (drafts / full proposal versus funded projects) 70% 63% 60% 50% 40% from drafts 40% 30% 16% from drafts 20% 23% 16% 10% 0 M. Karrasch, FZJ 13. 01. 2005 Austria Finland Germany Israel Latvia Slovenia Spain

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Part A: General Programme Description A 1: General Programme Information A 2: History and Road Map of the Programme A 3: Programme / Project statistics Part B: Programme management and implementation approaches B 1: Programme Initiation A: General Programme Description B 2: Application / Submission Procedure B 3: Evaluation Process B 4: Financial modalities, Legal and Contractual Framework B 5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Analysis: Funding possible impossible Partner Austria Finland France Germany Hungary Israel Latvia Portugal Slovenia Spain M. Karrasch, FZJ 13. 01. 2005 Synchronous calls with national funding Joint calls with transnational funding

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Analysis: cost models employed Country FC full cost with actual indirect costs FCF full cost with indirect flat rate costs AC additional costs with indirect flat rate costs other M. Karrasch, FZJ 13. 01. 2005 AT FI FR DE HU IL LV PT SV ES

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Part A: General Programme Description A 1: General Programme Information A 2: History and Road Map of the Programme A 3: Programme / Project statistics Part B: Programme management and implementation approaches B 1: Programme Initiation A: General Programme Description B 2: Application / Submission Procedure B 3: Evaluation Process B 4: Financial modalities, Legal and Contractual Framework B 5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Monitoring of ongoing projects Country AT FI FR DE HU IL LV 1/year PT SV ES 1/year Scientific/Technical Monitoring Written reports 1/year Oral reports/ interviews 1/year 1/year Site visit Seminar/conference 1/proj. Administrative/financial Monitoring Written reports 1/year 1 -4/ year 6/year Oral reports/ interviews Site visit Seminar/conference M. Karrasch, FZJ 13. 01. 2005 occasi onally 2/year 1/year

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Part A: General Programme Description A 1: General Programme Information A 2: History and Road Map of the Programme A 3: Programme / Project statistics Part B: Programme management and implementation approaches B 1: Programme Initiation A: General Programme Description B 2: Application / Submission Procedure B 3: Evaluation Process B 4: Financial modalities, Legal and Contractual Framework B 5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Relative economic Importance of Antiinfektives (2003) Partner Percentage of health expenses to GDP (%): percentage of pharmaceuticals to total health expenses (%): Total pharmaceutical retail market (maker’s price) (mio €): Anti-Infectives pharmaceutical retail market (mio €) Austria Finland France Germany 10, 8 15, 9 18. 900 1. 400 (7, 4%) 8, 8 17, 1 (1997) Slovenia 6, 2 15, 9 362 NA Spain (2002) M. Karrasch, FZJ 13. 01. 2005 7, 6 22, 0 12. 976 821 (6, 33%) Hungary Israel Latvia Portugal

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Most important anti-infektives selling companies (antiinfektives sales per year in mio €) Rank Germany Israel Slovenia Spain 1 RATIOPHARM (114) Teva Lek, d. d. (NA) Glaxo. Smith. Kline 2 BAYER (104) Rafa Krka, d. d. , Novo Mesto (0, 29) Aventis Pasteur MSD 3 PFIZER (96) Agis Esteve 4 AVENTIS (79) Farma Bayer 5 HEXAL (64) Lilly & Dista 6 GSK (51) Almirall Prodesfarma 7 ABBOTT (42) Farmacusi 8 FRESENIUS KAB. INTR (37) Vita Group 9 MSD (33) Bohm 10 ASTRAZENECA (32) M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Part A: General Programme Description A 1: General Programme Information A 2: History and Road Map of the Programme A 3: Programme / Project statistics Part B: Programme management and implementation approaches B 1: Programme Initiation A: General Programme Description B 2: Application / Submission Procedure B 3: Evaluation Process B 4: Financial modalities, Legal and Contractual Framework B 5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Resu lts of lands the nationa cape (expe l pathogen www. patho rtise mapp omics RT D geno mics- ing etc. ): (inter era. n nal pa et ges) M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Part A: General Programme Description A 1: General Programme Information A 2: History and Road Map of the Programme A 3: Programme / Project statistics Part B: Programme management and implementation approaches B 1: Programme Initiation A: General Programme Description B 2: Application / Submission Procedure B 3: Evaluation Process B 4: Financial modalities, Legal and Contractual Framework B 5: Project management, administrative procedures and Review of programme and projects Details on the national / regional Pathogenomics RTD landscape Research Content, Expertise Mapping, Economic Stakeholders M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Analysis: Type of Research Demonstration; 1 other ; 0 applied; 7 basic; 7 M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Analysis: Organisms studied – Phylogetenic Tree according to 16 S-r. RNA VII Green Sulfur Bacteria VIII Spirochaetes IX Deinococcus / Thermus VI Bacteroides Flavobacteria group V Planctomyces, Pirella IV Chlamydia X Green Nonsulfur Bacteria III Cyanobacteria XI Thermotoga II II Grampositive Bacteria Gram positive Bacteria XII Thermodesulfobacterium XIII Aquifex M. Karrasch, FZJ 13. 01. 2005 Proteobacteria IIProteobacteria

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Analysis: Organisms studied – Phylogetenic Tree according to 16 S-r. RNA VII Green Sulfur Bacteria VIII Spirochaetes IX Deinococcus / Thermus X Green Nonsulfur Bacteria XI Thermotoga XII Thermodesulfobacterium XIII Aquifex M. Karrasch, FZJ 13. 01. 2005 VI Bacteroides Flavobacteria group V Planctomyces, Pirella IV Chlamydia III Cyanobacteria II Gram positive Bacteria I Proteobacteria

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Analysis: Organisms studied II Gram positive Bacteria Gram-positive cocci: Gram-positive nonsporulating rods: e. g. Staphylococcus, Streptococcus, Pneumococcus e. g. Listeria, Mycobacterium, Corynebacterium Gram-positive sporulating rods: e. g. Bacillus, Clostridium Gram-positive bacteria without cell wall: Mycoplasma I Proteobacteria Gram-negative rods: IV Chlamydia Obligatory intracellular bacteria: Chlamydia VIII Spirochaetes Gram-negative spiral bacteria: e. g. Borellia, Treponema M. Karrasch, FZJ 13. 01. 2005 e. g. E. coli, Salmonella, Yersinia, Vibrio Haemophilus, Pasteurella, Helicobacter

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Organism groups studied Eukaryotic organisms fungi obl. intracellular bacteria Chlamydia Gram + cocci 15 10 33 Staphylococcus, Streptococcus Gram – spiral bacteria 5 Borrellia Gram + non-sporulating rods Listeria, Mycobacterium 17 Gram + sporulating rods 5 71 Bacillus, Clostridium 3 Gram + without cell wall Gram – rods E. coli, Salmonella, Klebsiella, Pseudomonas, Haemophilus, Bordetella, Vibrio, Helicobacter M. Karrasch, FZJ 13. 01. 2005 Mycoplasma

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Organism groups studied Eukaryotic organisms fungi obl. intracellular bacteria Chlamydia Gram + cocci 15 10 33 Staphylococcus, Streptococcus Gram – spiral bacteria 5 Borrellia Gram + non-sporulating rods Listeria, Mycobacterium 17 Gram + sporulating rods 5 71 Bacillus, Clostridium 3 Gram + without cell wall Gram – rods E. coli, Salmonella, Klebsiella, Pseudomonas, Haemophilus, Bordetella, Vibrio, Helicobacter M. Karrasch, FZJ 13. 01. 2005 Mycoplasma

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Gram-negative rods: which are the most common studied species? E. Coli spec. 7 E. Coli ETEC 5 (toxin producing) 6 3 3 Pseudomonas spec. M. Karrasch, FZJ 13. 01. 2005 5 3 3 Yersinia enterolitica 3 E. Coli EHEC (enterohaemorragic) Salmonella spec. Salmonella typhi Shigella spec. Yersinia spec.

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Gram-negative rods: which are the most committed countries? M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Organism groups studied Eukaryotic organisms fungi obl. intracellular bacteria Chlamydia Gram + cocci 15 10 33 Staphylococcus, Streptococcus Gram – spiral bacteria 5 Borrellia Gram + non-sporulating rods Listeria, Mycobacterium 17 Gram + sporulating rods 5 71 Bacillus, Clostridium 3 Gram + without cell wall Gram – rods E. coli, Salmonella, Klebsiella, Pseudomonas, Haemophilus, Bordetella, Vibrio, Helicobacter M. Karrasch, FZJ 13. 01. 2005 Mycoplasma

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Organism groups studied Enterococcus spec. 2 1 5 Pneumococcus spec. 2 Staphylococcus spec. 0 1 Staphylococcus aureus 7 5 Streptococcus pyogenes Streptococcus pneumoniae 2 Staphylococcus epidermidis 4 5 Streptococcus spec. M. Karrasch, FZJ 13. 01. 2005 1

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Gram-positive cocci: which are the most committed countries? M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Organism groups studied Eukaryotic organisms fungi obl. intracellular bacteria Chlamydia Gram + cocci 15 10 33 Staphylococcus, Streptococcus Gram – spiral bacteria 5 Borrellia Gram + non-sporulating rods Listeria, Mycobacterium 17 Gram + sporulating rods 5 71 Bacillus, Clostridium 3 Gram + without cell wall Gram – rods E. coli, Salmonella, Klebsiella, Pseudomonas, Haemophilus, Bordetella, Vibrio, Helicobacter M. Karrasch, FZJ 13. 01. 2005 Mycoplasma

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Gram-positive non-sporulating rods : which are the most common studied species? 1 2 Streptomyces spec. 5 Listeria monocytogenes 1 Mycobacterium bovis 2 Mycobacterium tuberculosis M. Karrasch, FZJ 13. 01. 2005 4 3 Mycobacterium spec.

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Gram-positive non-sporulating rods : which are the most committed countries? Spain; 5 Germany; 3 Israel; 1 Austria Finland Germany Israel Latvia; 2 Latvia Slovenia Spain; 5 M. Karrasch, FZJ 13. 01. 2005 Slovenia; 2 Spain

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Organism groups studied Eukaryotic organisms fungi obl. intracellular bacteria Chlamydia Gram + cocci 15 10 33 Staphylococcus, Streptococcus Gram – spiral bacteria 5 Borrellia Gram + non-sporulating rods Listeria, Mycobacterium 17 Gram + sporulating rods 5 71 Bacillus, Clostridium 3 Gram + without cell wall Gram – rods E. coli, Salmonella, Klebsiella, Pseudomonas, Haemophilus, Bordetella, Vibrio, Helicobacter M. Karrasch, FZJ 13. 01. 2005 Mycoplasma

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Eukaryotic Organisms: which are the most common studied ones? other; 4 Yeast 3 Yeast Aspergillus Echinococcus 1 Aspergillus 4 Candida other (please specify) - other: Trypanosoma Leishmania 3 Plasmodium 2 Plasmodium Candida 2 Leishmania Echinococcus granulo other (please specify) M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Eukaryotic Organisms: which are the most committed countries? Finland; 1 Spain; 5 Israel; 3 Austria Finland Germany Israel Latvia Slovenia; 4 Spain; 5 M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape M. Karrasch, FZJ 13. 01. 2005

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Analysis: Organisms studied – Phylogetenic Tree according to 16 S-r. RNA VII Green Sulfur Bacteria Alpha: VI Bacteroides Flavobacteria group e. g. Acetobacter, Agrobacterium, Gluconobacter, Paracoccus, Rhodospirillum, V Planctomyces, Pirella VIII Spirochaetes Rhizobium, Zymomonas Beta: IX Deinococcus / Pseudomonas (some), Spirillum e. g. Neisseria, Thermus IV Chlamydia Gamma: Nonsulfur Bacteria X Green e. g. Escherichia, Legionella, Salmonella and other intestine bacteria, Vibrio III Cyanobacteria Delta: XI e. g. sulfate reducing bacteria, Myxobacteria, Xanthomonas (some) Thermotoga II Gram positive Bacteria Epsilon: e. g. XII Thermo- Campylobacter, Helicobacter, Xanthomonas (some) desulfobacterium XIII Aquifex M. Karrasch, FZJ 13. 01. 2005 I Proteobacteria

ERA-NET Patho. Geno. Mics WP 1 Status-quo of partner programmes T 1. 1 Survey national programmes/RTD landscape Analysis: Organisms studied – Phylogetenic Tree according to 16 S-r. RNA VII Green Sulfur Bacteria VI Bacteroides Flavobacteria group Non sporulating gram+ bacteria, low G+C content: V Planctomyces, Pirella VIII Spirochaetes e. g. Staphylococcus, Streptococcus, Micrococcus, Lactobacillus, Enterococcus, Listeria IV Chlamydia IX Deinococcus / Thermus Endosporulating gram+ bacteria, low G+C content: e. g. Bacillus, Clostridium X Green Nonsulfur Bacteria III Cyanobacteria Bacteria without cell wall: Mycoplasma XI Thermotoga II Gram positive Bacteria gram+ bacteria, high G+C content: e. g. XII Thermo- Corynebacterium, Mycobacterium, Actinomycetes desulfobacterium XIII Aquifex M. Karrasch, FZJ 13. 01. 2005 I Proteobacteria